Professor Eisen is a clinical trialist interested in developing new treatments for advanced disease, identifying and managing those at risk of disease. His current clinical interests are the research and management of kidney cancer. In kidney cancer, he has been particularly involved in the development of tyrosine kinase inhibitors as therapeutic agents.
He is currently on 5 years partial leave of absence to work in AstraZeneca, where I am currently responsible for oncology trials from first in man to Phase II.
Kidney cancer, early lung cancer, immunology, anti-angiogenic therapy
Management of Renal Cancer, Lung Cancer and Pre-malignant Lung Disease.
Pubmed journal articles - pubmed
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2): 125-34
Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006 Sep 4;95(5):581-6.
Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS. Nat Genet. 2008 May;40(5):616:22
Oncology editor of the Oxford Textbook of Medicine
